TNFSF10
Reactivity: Human
WB
Host: Rabbit
Polyclonal
unconjugated
Application Notes
Neutralization: To yield one-half maximal inhibition [ND50] of the biological activity ofhTRAIL/Apo2L (30 ng/mL), a concentration of 0.5 - 0.8 μg/mL of this antibody is required. ELISA: To detect hTRAIL/Apo2L by direct ELISA (using 100 l/well antibody solution) aconcentration of at least 0.5 μg/mL of this antibody is required. This antigen affinitypurified antibody, in conjunction with compatible secondary reagents, allows the detectionof 0.2 - 0.4 ng/well of recombinant hTRAIL/Apo2L. Western Blot: To detect hTRAIL/Apo2L by Western Blot analysis this antibody can be usedat a concentration of 0.1 - 0.2 μg/mL. Used in conjunction with compatible secondaryreagents the detection limit for recombinant hTRAIL/Apo2L is 1.5 - 3.0 ng/lane, under eitherreducing or non-reducing conditions. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions
For Research Use only
Reconstitution
Restore in sterile water to a concentration of 0.1-1.0 mg/mL.
Buffer
PBS, pH 7.2 without preservatives.
Preservative
Without preservative
Handling Advice
Avoid repeated freezing and thawing. Centrifuge vial prior to opening!
Storage
4 °C/-20 °C
Storage Comment
Store the antibody prior to reconstitution at -20 °C. Following reconstitution the antibody can be stored at 2-8 °C for one month or at -20 °C for longer.
Target
TRAIL (TNFSF10)
(Tumor Necrosis Factor (Ligand) Superfamily, Member 10 (TNFSF10))
Apoptosis or programmed cell death is induced in cells by a group of death domain containing receptors. Binding of ligand to these receptors sends signals that activate members of the caspase family of proteases. The signals ultimately cause degradation of chromosomal DNA by activating DNase. TRAIL (TNF related apoptosis induced ligand) or Apo 2L initiates apoptosis of tumor cells by binding to either of its receptors, DR4 or DR5. These receptors consist of an extracellular TRAIL binding domain and a cytoplasmic "death domain". In addition, two decoy receptors for TRAIL have also been identified. These receptors, designated DcR1 and DcR2, lack the death domain. Binding of TRAIL to either of these receptors, therefore, does not transmit the death signal. Thus, these receptors represent a novel way of regulating cell sensitivity to a pro-apoptotic cytokine at the cell surface. TRAIL is expressed predominantly in spleen, lung, and prostate but also in many other tissues.Synonyms: APO2L, Apo-2 ligand, Apo-2L, TNF-related apoptosis-inducing ligand, TNFSF10, Tumor necrosis factor ligand superfamily member 10